M. Nucci et al., CEFTAZIDIME PLUS AMIKACIN PLUS TEICOPLANIN OR VANCOMYCIN IN THE EMPIRICAL ANTIBIOTIC-THERAPY IN FEBRILE NEUTROPENIC CANCER-PATIENTS, Oncology Reports, 5(5), 1998, pp. 1205-1209
A prospective randomized trial was performed to compare teicoplanin to
vencomycin as part of the empirical antibiotic therapy of febrile neu
tropenic cancer patients. Fifty-three patients were randomized to rece
ive ceftazidime (100 mg/kg daily every 8 h), amikacin (15 mg/kg daily
every 8 h) and teicoplanin (6 mg/kg once a day) and 53 other patients
received ceftazidime, amikacin (same dosages) and vancomycin (30 mg/kg
/day every 6 h). In 99 evaluable episodes, the success rates were 54%
for patients receiving teicoplanin and 52% for patients receiving vanc
omycin (p=0.76, 95% CI-18-23). The response rates were similar for pat
ients with un explained fever and for patients with documented infecti
ons. There were no differences in renal toxicity or cutaneous side eff
ects between the two groups. The overall death rate was 18.9%, with 10
deaths in each group. The most important factor associated with death
was the diagnosis of a fungal infection (p=0.001). Teicoplanin seems
to be well tolerated and as effective as vancomycin in the empirical a
ntibiotic therapy of fever in neutropenic cancer patients.